174 related articles for article (PubMed ID: 36313397)
1. CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy.
Meshitsuka S; Ninomiya R; Nagamura-Inoue T; Okada T; Futami M; Tojo A
Regen Ther; 2022 Dec; 21():442-452. PubMed ID: 36313397
[TBL] [Abstract][Full Text] [Related]
2. Generation of Mesenchymal Stromal Cells with Low Immunogenicity from Human PBMC-Derived β2 Microglobulin Knockout Induced Pluripotent Stem Cells.
Zha S; Tay JC; Zhu S; Li Z; Du Z; Wang S
Cell Transplant; 2020; 29():963689720965529. PubMed ID: 33172291
[TBL] [Abstract][Full Text] [Related]
3. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
[TBL] [Abstract][Full Text] [Related]
4. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Graft-versus-Host-Disease in NOD.Cg-Prkdc
Hansen M; Stahl L; Heider A; Hilger N; Sack U; Kirschner A; Cross M; Fricke S
Transplant Cell Ther; 2021 Aug; 27(8):658.e1-658.e10. PubMed ID: 33964513
[TBL] [Abstract][Full Text] [Related]
6. T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.
Gaykema LH; van Nieuwland RY; Lievers E; Moerkerk WBJ; de Klerk JA; Dumas SJ; Kers J; Zaldumbide A; van den Berg CW; Rabelink TJ
Stem Cells Transl Med; 2024 Jan; 13(1):69-82. PubMed ID: 37843402
[TBL] [Abstract][Full Text] [Related]
7. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
[TBL] [Abstract][Full Text] [Related]
8. Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection.
Shao L; Zhang Y; Pan X; Liu B; Liang C; Zhang Y; Wang Y; Yan B; Xie W; Sun Y; Shen Z; Yu XY; Li Y
Cell Mol Life Sci; 2020 Mar; 77(5):937-952. PubMed ID: 31312880
[TBL] [Abstract][Full Text] [Related]
9. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
10. Comparing the Benefits and Drawbacks of Stem Cell Therapy Based on the Cell Origin or Manipulation Process: Addressing Immunogenicity.
Chang SH; Park CG
Immune Netw; 2023 Dec; 23(6):e44. PubMed ID: 38188600
[TBL] [Abstract][Full Text] [Related]
11. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
[TBL] [Abstract][Full Text] [Related]
12. Generation of a B2M homozygous knockout human somatic cell nuclear transfer-derived embryonic stem cell line using the CRISPR/Cas9 system.
Lee OH; Lee S; Park M; Moon S; Hwang S; Kim B; Kim CY; Lee DR; Shim SH; Park KH; Chung HM; Choi Y
Stem Cell Res; 2022 Mar; 59():102643. PubMed ID: 34971932
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
Front Immunol; 2019; 10():619. PubMed ID: 31001253
[TBL] [Abstract][Full Text] [Related]
14. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.
Gornalusse GG; Hirata RK; Funk SE; Riolobos L; Lopes VS; Manske G; Prunkard D; Colunga AG; Hanafi LA; Clegg DO; Turtle C; Russell DW
Nat Biotechnol; 2017 Aug; 35(8):765-772. PubMed ID: 28504668
[TBL] [Abstract][Full Text] [Related]
15. Stromal Cells Act as Guardians for Endothelial Progenitors by Reducing Their Immunogenicity After Co-Transplantation.
Souidi N; Stolk M; Rudeck J; Strunk D; Schallmoser K; Volk HD; Seifert M
Stem Cells; 2017 May; 35(5):1233-1245. PubMed ID: 28100035
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.
Selmani Z; Naji A; Zidi I; Favier B; Gaiffe E; Obert L; Borg C; Saas P; Tiberghien P; Rouas-Freiss N; Carosella ED; Deschaseaux F
Stem Cells; 2008 Jan; 26(1):212-22. PubMed ID: 17932417
[TBL] [Abstract][Full Text] [Related]
17. Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells.
Kwon D; Ahn HJ; Han MJ; Ji M; Ahn J; Seo KW; Kang KS
Stem Cell Rev Rep; 2020 Aug; 16(4):792-808. PubMed ID: 32712868
[TBL] [Abstract][Full Text] [Related]
18. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
[TBL] [Abstract][Full Text] [Related]
19. Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins.
Shi L; Li W; Liu Y; Chen Z; Hui Y; Hao P; Xu X; Zhang S; Feng H; Zhang B; Zhou S; Li N; Xiao L; Liu L; Ma L; Zhang X
Stem Cells; 2020 Nov; 38(11):1423-1437. PubMed ID: 32930470
[TBL] [Abstract][Full Text] [Related]
20. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases.
Mebarki M; Iglicki N; Marigny C; Abadie C; Nicolet C; Churlaud G; Maheux C; Boucher H; Monsel A; Menasché P; Larghero J; Faivre L; Cras A
Stem Cell Res Ther; 2021 Nov; 12(1):571. PubMed ID: 34774107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
